Elisa Catanzaro

Dr. Elisa Catanzaro

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ECElisa Catanzaro
Elisa Catanzaro
Enrico GringeriEnrico Gringeri
Enrico Gringeri
PBPatrizia Burra
Patrizia Burra
MGMARTINA GAMBATO
MARTINA GAMBATO
Cholangiocarcinoma (CCA) is the most common malignancy in patients with primary sclerosing cholangitis (PSC), accounting for 2–8% of cases and being the leading cause of death in these patients. The majority of PSC-associated CCAs (PSC-CCA) develop within the first few years after PSC diagnosis. Older age and male sex, as well as concomitant inflammatory bowel disease (IBD) or high-grade biliary stenosis, are some of the most relevant risk factors. A complex combination of molecular mechanisms involving inflammatory pathways, direct cytopathic damage, and epigenetic and genetic alterations are involved in cholangiocytes carcinogenesis. The insidious clinical presentation makes early detection difficult, and the integration of biochemical, radiological, and histological features does not always lead to a definitive diagnosis of PSC-CCA. Surveillance is mandatory, but current guideline strategies failed to improve early detection and consequently a higher patient survival rate. MicroRNAs (miRNAs), gene methylation, proteomic and metabolomic profile, and extracellular vesicle components are some of the novel biomarkers recently applied in PSC-CCA detection with promising results. The integration of these new molecular approaches in PSC diagnosis and monitoring could contribute to new diagnostic and surveillance strategies.

28 February 2024 in Medicina
Verified
Journal Article
Open access
PDF file
SBSara Battistella
Sara Battistella
MGMarco Grasso
Marco Grasso
ECElisa Catanzaro
Elisa Catanzaro
FDFrancesca D'Arcangelo
Francesca D'Arcangelo
GCGiorgia Corrà
Giorgia Corrà
Francesco RussoFrancesco Russo
Francesco Russo
Liver transplantation (LT) has significantly transformed the prognosis of patients with end-stage liver disease and hepatocellular carcinoma (HCC). The traditional epidemiology of liver diseases has undergone a remarkable shift in indications for LT, marked by a decline in viral hepatitis and an increase in metabolic dysfunction-associated steatotic liver disease (MASLD), along with expanded indications for HCC. Recent advancements in surgical techniques, organ preservation and post-transplant patients’ management have opened new possibilities for LT. Conditions that were historically considered absolute contraindications have emerged as potential new indications, demonstrating promising results in terms of patient survival. While these expanding indications provide newfound hope, the ethical dilemma of organ scarcity persists. Addressing this requires careful consideration and international collaboration to ensure equitable access to LT. Multidisciplinary approaches and ongoing research efforts are crucial to navigate the evolving landscape of LT. This review aims to offer a current overview of the primary emerging indications for LT, focusing on acute-on-chronic liver failure (ACLF), acute alcoholic hepatitis (AH), intrahepatic and perihilar cholangiocarcinoma (i- and p-CCA), colorectal liver metastasis (CRLM), and neuroendocrine tumor (NET) liver metastases.

7 January 2024 in Tomography
Verified
Journal Article
Open access
PDF file
NCNora Cazzagon
Nora Cazzagon
SSSamantha Sarcognato
Samantha Sarcognato
ECElisa Catanzaro
Elisa Catanzaro
EBEmanuela Bonaiuto
Emanuela Bonaiuto
MPMatteo Peviani
Matteo Peviani
RMRaffaella Motta
Raffaella Motta
Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by inflammation and fibrosis of intra- and/or extrahepatic bile ducts leading to the formation of multifocal strictures alternated to bile duct dilatations. The diagnosis of the most common subtype of the disease, the large duct PSC, is based on the presence of elevation of cholestatic indices, the association of typical cholangiographic findings assessed by magnetic resonance cholangiography and the exclusion of causes of secondary sclerosing cholangitis. Liver biopsy is not routinely applied for the diagnosis of large duct PSC but is mandatory in the case of suspicion of small duct PSC or overlap with autoimmune hepatitis.

20 February 2024 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
ECElisa Catanzaro
Elisa Catanzaro
Enrico GringeriEnrico Gringeri
Enrico Gringeri
NCNora Cazzagon
Nora Cazzagon
AFAnnarosa Floreani
Annarosa Floreani
Umberto CilloUmberto Cillo
Umberto Cillo
MGMARTINA GAMBATO
MARTINA GAMBATO
Background: Primary sclerosing cholangitis (PSC), comprising 5–15% of European liver transplantation (LT) cases, poses a significant challenge due to the risk of post-transplant disease recurrence (rPSC). This single-center study aimed to determine the rPSC rate and long-term post-LT outcomes in PSC patients and to identify potentially modifiable risk factors of rPSC. Methods: All PSC patients receiving LT at Padua Hospital from 1993 to 2021 were included. Recipient data were collected pre-LT, at LT, and during the follow-up. Donor and LT features were recorded. The rPSC rate was assessed according to Mayo Clinic criteria. Patient and graft survival were reported. Results: Thirty-three patients were included. The main indication of LT was decompensated cirrhosis (70%). Nine patients (27%) developed rPSC during a median follow-up of 59 months (45–72). A longer cold ischemia time (p = 0.026), donor female gender (p = 0.049), inflammatory bowel disease reactivation (IBD) post LT (p = 0.005) and hepaticojejunostomy (p = 0.019) were associated with a higher risk of rPSC. Graft and patient survival at 1, 5 and 10 years post LT, 94%, 86%, 74% and 97%, 89%, 77% respectively, were not affected by rPSC development. Conclusion: Specific donor and surgical features might increase the risk of rPSC. Identifying predictive factors for rPSC to prevent graft loss is challenging but could lead to a more personalized organ allocation and follow-up in PSC transplanted patients. IBD reactivation might have a pathogenic role in rPSC. In our single-center experience, rPSC did not affect patient and graft survival.

16 April 2025 in Hepatology
Verified
Journal Article
Open access
MHMagnus Holmer
Magnus Holmer
MIMichael Ingre
Michael Ingre
MFMartti Färkkilä
Martti Färkkilä
CPCyriel Y Ponsioen
Cyriel Y Ponsioen
BMBregje Mol
Bregje Mol
ABAnnika Bergquist
Annika Bergquist
Background and Aims: The risk of HCC in primary sclerosing cholangitis (PSC) is unclear. Studies indicate a low risk for HCC, questioning the rationale for current HCC surveillance guidelines. This study explores the risk of HCC in a longitudinal multicenter cohort with over 3000 PSC subjects. Approach and Results: Subjects with well-characterized PSC (n=3071) were followed at 12 university hospitals within the International PSC Registry (IPSCR) collaboration for a total of 38,387 person-years. Incident HCC was registered. Subjects were followed from PSC diagnosis until death, liver transplantation, diagnosis of hepatobiliary malignancy, or February 2024. Poisson regression was used to calculate incidence rate ratios for HCC for the total population and for subgroups of different ages and cirrhosis status. Thirty-nine subjects developed HCC after a mean time of 16.4 years (SD ±10.7) from PSC diagnosis. In 26 (66.7%) of HCC cases, cirrhosis was diagnosed before HCC. The mean age at HCC diagnosis was 55.6 years (±SD13.1 years), and 28 (71.8%) were male. HCC was associated with cirrhosis (IRR: 10.8, 95% CI: 5.7–20.5) and age (IRR 1.05, 95% CI: 1.03–1.08). At the age of 50, the incidence rate was 0.81 and 0.47 for cirrhotic men and women, respectively. For non-cirrhotic subjects, the risk was low for both men and women and all age groups. Conclusion: HCC is relatively rare in patients with primary sclerosing cholangitis who do not have cirrhosis, especially in those under the age of 50. Our findings indicate that HCC monitoring for patients with PSC can be tailored based on their age and cirrhosis status.

12 May 2026 in Digestive and Liver Disease
Verified
Journal Article
Open access
ECElisa Catanzaro
Elisa Catanzaro
MPM. Peviani
M. Peviani
EBE. Bonaiuto
E. Bonaiuto
FPF. Pezzato
F. Pezzato
MBM. Benatti
M. Benatti
NCNora Cazzagon
Nora Cazzagon
Fibrates may improve cholestasis and pruritus in Primary Sclerosing Cholangitis (PSC), but long-term data is limited. This study assessed the safety and biochemical, radiological, and clinical effects of fibrates in PSC. We retrospectively analysed PSC patients on stable UDCA therapy who received add-on fibrates between 2017 and 2025. Clinical, biochemical, radiological, and elastography data were collected to assess treatment response, safety, and disease progression. Of 37 PSC patients initiating fibrates, 34 were included, 21% with cirrhosis. Fenofibrate was used in 88% for a median of 34 months. Significant reductions in ALP, GGT, and ALT were observed at 6 months and sustained over follow-up. The proportion of patients with ALP < 1.5 × ULN increased from 22% to 45% at 6 months. The Amsterdam-Oxford score (AOM) decreased significantly at 6 and 12 months (p = 0.02). Responders had lower baseline bilirubin, transaminases, AOM, and Mayo Risk score (p < 0.05). Pruritus improved while fatigue, cholangitis frequence, and liver stiffness remain unchanged. MRI follow-up showed worsening of ANALI score due to bile duct dilatation, with stable DiStrict score. Adverse events occurred in 15%, leading to discontinuation in 4 patients. Fibrates appear to be a safe and potentially effective option in PSC, especially in early-stage disease, pending confirmation from prospective trials.